引用本文: | 王燕靖,沈宁,罗彬,赵英伦,陆绍龙,叶小龙,张沅,张煜萱,谢小薰.癌-睾丸抗原NY-SAR-35在结直肠癌中的表达及临床预后意义[J].中国临床新医学,0,():-. |
| WANG Yan-jing,SHEN Ning,LUO Bin,ZHAO Ying-lun,LU Shao-long,YE Xiao-long,ZHANG Yuan,ZHANG Yu-xuan,XIE Xiao-xun.癌-睾丸抗原NY-SAR-35在结直肠癌中的表达及临床预后意义[J].中国临床新医学,0,():-. |
|
|
|
本文已被:浏览 389次 下载 0次 |
|
|
癌-睾丸抗原NY-SAR-35在结直肠癌中的表达及临床预后意义 |
王燕靖1, 沈宁2, 罗彬1, 赵英伦1, 陆绍龙1, 叶小龙1, 张沅1, 张煜萱1, 谢小薰1
|
1.广西医科大学基础医学院组织学与胚胎学教研室;2.广西壮族自治区人民医院
|
|
摘要: |
目的 检测癌-睾丸抗原NY-SAR-35在结直肠癌(Colorectal cancer ,CRC)患者中的表达情况,并分析其临床预后意义。方法 收集59例结直肠癌及其匹配的癌旁组织标本,采用逆转录-聚合酶链反应(Reverse Transcription Polymerase Chain Reaction,RT-PCR)检测NY-SAR-35的表达,分析其与患者临床病理参数的关系,并绘制 Kaplan-Meier 生存曲线,进行多因素 Cox 回归模型分析独立预后因素。结果 NY-SAR-35 mRNA在结直肠癌组织中的表达阳性率(35.59%,21/59)显著高于癌旁组织(13.56%,8/59),二者差异具有统计学意义 (P<0.05);NY-SAR-35 mRNA的表达与患者性别、年龄、肿瘤位置、CEA水平、肿瘤浸润深度、淋巴结转移、远处转移、TNM分期、组织学类型和肿瘤分化程度等临床病理参数无关,但与肿瘤大小和患者生存状态相关;进一步生存曲线显示NY-SAR-35不表达的结直肠癌患者生存期明显优于NY-SAR-35 阳性表达患者(57.24 vs 40.71,P<0.05 ),Cox 回归模型分析则发现肿瘤浸润深度、淋巴结转移、远处转移和NY-SAR-35表达均为影响结直肠癌生存的独立预后因素(P<0.05 )。结论 NY-SAR-35 在结直肠癌高表达且影响患者预后,可作为结直肠癌潜在的预后标志物和治疗靶点。 |
关键词: 大肠癌 癌-睾丸抗原 NY-SAR-35 表达 预后 |
DOI: |
分类号: |
基金项目:国家自然科学基金(81960453, 81860445)、广西自然科学基金(2018GXNSFAA050058)、广西区域性高发肿瘤早期防治研究教育部重点实验室课题(GK2019-08, GKE-ZZ202006)共同资助。 |
|
Expression and clinical prognostic significance of NY-SAR-35 in colorectal cancer |
WANG Yan-jing,SHEN Ning,LUO Bin,ZHAO Ying-lun,LU Shao-long,YE Xiao-long,ZHANG Yuan,ZHANG Yu-xuan,XIE Xiao-xun
|
Guangxi Medical University
|
Abstract: |
Objective To detect the expression of cancer/testis (CT) antigens NY-SAR-35 in colorectal cancer (CRC) and evaluate its clinicopathological and prognostic significance. Methods 59 paired CRC and corresponding adjacent normal tissues were collected to detect the expression of NY-SAR-35 by Reverse Transcription Polymerase Chain Reaction (RT-PCR). Subsequently, the relationship between NY-SAR-35 expression and clinicalpathological parameters were statistically analyzed. Furthermore, Kaplan-Meier survival curves were plotted and independent prognostic factors were analyzed by multivariate cox regression analysis. Result The positive rates for NY-SAR-35 mRNA expression in colorectal cancer tissues (35.59%, 21/59) were significantly higher than that in para-cancerous tissue (13.56%, 8/59) and the difference was statistically significant (P<0.05). NY-SAR-35 mRNA expression was significantly associated with tumor size and survival state, but not with gender, age, tumor location, CEA level, tumor infiltration depth, lymph node metastasis, distant metastasis, TNM stage, histological type and tumor differentiation. Furthermore, Kaplan-Meier survival curves showed that CRC patients with no NY-SAR-35 expression had longer overall survival than those with positive NY-SAR-35 expression(57.24 vs 40.71,P<0.05 ). Cox regression analysis found tumor invasion depth, lymph node metastasis, distant metastasis and NY-SAR-35 expression were identified as independent prognostic factors for CRC (P<0.05). Conclusion NY-SAR-35 was upregulated and associated with poor prognosis in patients with CRC, suggesting that NY-SAR-35 may act as a potential biomarker and therapeutic target for CRC . |
Key words: Colorectal cancer Cancer-testis antigen NY-SAR-35 Expression prognosis. |
|
|
|
|